Cardio Diagnostics 3Q 2026: Revenue $3.59K, EPS ($0.59) — 10-Q Summary

Cardio Diagnostics reported 3Q 2026 revenue of $3.59K, up 25.7% YoY, but net loss widened to $1.73M. The company added providers, began lab testing, and expanded coverage for its tests. EPS loss narrowed to $0.59 from $0.98.

Original reporting
Published Nov 6, 2026, 1:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 1:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Cardio Diagnostics 3Q 2026: Revenue $3.59K, EPS ($0.59) — 10-Q Summary — source image
Decision brief

The 30-second read

$CDIONeutralLow
01

Why it matters

The Q3 earnings indicate growth in revenue but continued operational losses, suggesting a mixed short‑term outlook.

02

Market read

Earnings release for a niche health‑tech micro‑cap; limited impact on broader markets.

03

What to watch

Potential future upside from new CLIA lab operations and expansion into India could improve margins.

Relevance 6/10Novelty 6/10Timing: post-market release

Background

Cardio Diagnostics is a micro‑cap company providing cardiac diagnostic tests, recently expanding its provider network and lab capabilities.

Company-level read

Ticker impact

$CDIONeutralMedium confidence
Context

Cardio Diagnostics reported Q3 2026 revenue of $3.59M, a 25.7% YoY increase, and a narrowed net loss.

Expected impact

limited upside as revenue beats expectations, but pressure from widening loss may cap gains

Evidence & confidence

Revenue beat suggests demand growth, yet expanding SG&A and net loss may dampen investor enthusiasm.

Market effects

Highlights ongoing demand for cardiac diagnostics, modestly positive for the broader health‑tech sector.

Primarily affects US micro‑cap investors; limited broader market effect.

Low global relevance beyond niche diagnostic market.

Counterpoint

Despite revenue growth, the widening loss and high SG&A suggest the stock may face further downside.

Key entities

  • Cardio Diagnostics Holdings, Inc.

    Issuer of the earnings report.

Related articles

$WBMedAI 8/10

Alibaba Is Pulling Back From This 10% Dividend Stock

Weibo (WB) missed Q3 revenue and earnings expectations, with advertising revenue from Alibaba (BABA) falling 33%. Shares dropped 4% premarket. GAAP net income fell 88.91%, operating cash flow turned negative, and long-term loans were reclassified as current. The dividend yield is 10.6%, but earnings are declining. CEO Gaofei Wang highlighted AI efforts, but ad budgets remain a concern.

$SLSHighAI 9/10

SELLAS Gets A REGAL Boost As Immunotherapeutic Cancer Vaccine Trial Meets Primary Endpoint

SELLAS Life Sciences (SLS) reported positive Phase 3 REGAL trial results for its cancer vaccine, Galinpepimut-S (GPS), meeting the primary endpoint of overall survival. GPS reduced the risk of death by 41% compared to standard treatment, with median OS of 24.0 months vs. 14.7 months. The company plans to discuss an accelerated FDA filing pathway and aims for a BLA submission in early 2027. Shares surged over 255% in premarket trading.

$RIMEMed

Algorhythm Holdings Reports Third Quarter 2026 Financial Results

Algorhythm Holdings, Inc. (RIME) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Algorhythm Holdings Reports Third Quarter 2026 Financial Results Company Completes Azure Energy Acquisition and Begins Strategic Restructuring Fort Lauderdale, FL, November 17, 2026 – Algorhythm Holdings, Inc. (the “Company”) (NASDAQ: RIME ), a diversified holding co

$JDMedAI 8/10

JD.com returns to revenue growth as third-quarter profit misses estimates

JD.com reported Q3 revenue growth of 3.5% to 309.59 billion yuan, beating estimates. Net income rose 23% to 6.5 billion yuan but missed expectations. Electronics revenue fell 0.7%, while general merchandise rose 8.1%. Operating income turned positive. Shares fell in premarket trading. The company expanded its user base and completed a stake acquisition in Ceconomy.